Neostrata Problem Dry Skin Cream 100g
NeoStrata
Cosmetic skincare – targeted body treatmentKeratolytic AHA/PHA cream for severely dry, rough and hyperkeratotic skin
Certifications
- Marketed and regulated as a cosmetic/dermocosmetic product in relevant territories and not as a medicinal product or medical device.
- Ingredient labelling (INCI) and claims are published on official NeoStrata pages and authorised retailers, consistent with cosmetic regulatory requirements in the UK/EU markets.
- Marketed and regulated as a cosmetic/dermocosmetic product in relevant territories and not as a medicinal product or medical device.
- Ingredient labelling (INCI) and claims are published on official NeoStrata pages and authorised retailers, consistent with cosmetic regulatory requirements in the UK/EU markets.
Keratolytic AHA/PHA cream for severely dry, rough and hyperkeratotic skin
Description
Neostrata Problem Dry Skin Cream 100g is a rich, dermatologist-developed AHA/PHA body cream formulated for severely dry, rough and thickened skin, particularly on areas such as knees, elbows and heels. The formula contains a high 20% Hydroxy Acid blend (AHA/PHA) together with Maltobionic Acid and Pro-Vitamin E to exfoliate and hydrate hyperkeratotic skin. The highly emollient base with beeswax and skin-conditioning oils helps to instantly reduce skin roughness on contact. NeoStrata state that significant improvement in heavily calloused skin can be seen in as little as three weeks of once-daily use. The product is fragrance-free and has an approximate pH of 3.6.
Bnefits
- Formulated with a 20% Hydroxy Acid blend (AHA/PHA) to exfoliate and smooth severely dry, rough and thickened skin.
- Targets problem areas such as knees, elbows and heels and is suitable for thickened, calloused skin.
- Highly emollient vehicle (beeswax and skin-conditioning oils) reduces roughness on contact and improves spreadability.
- Contains Maltobionic Acid and Pro-Vitamin E for added hydration and antioxidant support.
- Fragrance-free formulation with amphoteric buffering to help reduce irritation risk compared with similarly high-strength AHA products.
- Clinically reported improvement in heavily calloused skin within approximately 3 weeks of daily use (per manufacturer/retailer claims).
Indications
- Severely dry, rough and thickened skin (hyperkeratosis) unresponsive to conventional moisturisers.
- Heavily calloused areas such as knees, elbows and heels requiring intensive exfoliation and moisturisation.
- Adjunctive cosmetic care to help soften psoriasis plaques and rough, scaly skin on non-facial body sites as part of a skincare regimen.
Composition
- Active/functional actives: 20% Hydroxy Acid blend (combination of AHAs and PHAs) including Glycolic Acid, Lactic Acid, Mandelic Acid and Gluconolactone; Maltobionic Acid.
- Skin-conditioning and emollient ingredients: Petrolatum, Mineral Oil, Cera Alba (Beeswax), Cetyl Alcohol, Stearyl Alcohol, Caprylic/Capric Triglyceride, Dimethicone.
- Antioxidant: Pro-Vitamin E (Tocopheryl Acetate).
- Other ingredients (INCI as published by NeoStrata / authorised retailers): Aqua (Water), Propylene Glycol, Petrolatum, Mineral Oil, Glycolic Acid, Lactic Acid, Mandelic Acid, Gluconolactone, Stearyl Alcohol, Cera Alba (Beeswax), PEG-40 Stearate, Sorbitan Stearate, Arginine, Ammonium Hydroxide, Maltobionic Acid, Cetyl Alcohol, Dimethicone, Tocopheryl Acetate, Magnesium Aluminium Silicate, Xanthan Gum, Disodium EDTA, Sodium Bisulfite, Methylparaben, Propylparaben, CI 19140, CI 17200.
Formulation
- Rich, emollient cream formulation (wash-off not intended) for localised body application.
- High-strength keratolytic formula (20% AHA/PHA) with amphoteric buffering (pH ~3.6) to balance efficacy and tolerability.
- Fragrance-free, dermatologist-developed targeted treatment for hyperkeratotic skin sites.
Packaging
- Supplied as a 100 g (3.4 fl oz) tube (branded NeoStrata tube with flip cap) and sold as a single retail unit.
- Outer carton included where sold through authorised retailers; full carton artwork and batch labelling present in retail packaging.
Usage
- Apply to affected areas once daily (some sources report once- or twice-daily use depending on tolerance; manufacturer guidance and retailer listings typically recommend once daily for problem dry skin).
- For initial intensive treatment, follow product guidance; significant improvement has been reported after approximately 3 weeks of daily use.
- Avoid application to broken, inflamed or eczema-affected skin unless advised by a clinician.
- Because of the high AHA content, avoid excessive sun exposure on treated areas and use broad-spectrum sunscreen on exposed skin during treatment and for one week after discontinuation.
- If irritation occurs, reduce frequency of application or discontinue and consult a skincare professional.
Contraindications
- Not publicly listed as formal medical contraindications (cosmetic product).
- General caution: do not use if hypersensitive to any ingredient in the INCI list (e.g. AHAs, beeswax, parabens or colourants).
- Avoid use on broken or acutely inflamed skin; seek professional advice for use on sensitive areas or in patients with active dermatological disease.
Adverse Effects
- Not published as a medicinal adverse-event table; potential reactions consistent with high-strength AHA/PHA products include stinging, burning, transient redness, peeling and increased sun sensitivity in susceptible individuals.
- Allergic contact dermatitis or irritation may occur in sensitive persons; discontinue use if severe irritation develops.
Storage Conditions
- Not specifically detailed in public retail listings; follow general cosmetic storage: store in original packaging, in a cool, dry place away from direct sunlight and excessive heat, and keep out of reach of children.
Duration
Not strictly defined; labelled and marketed for ongoing targeted use on problem areas. Manufacturer/retailer literature cites measurable improvement in heavy callus within approximately 3 weeks of once-daily use.
Onset
Significant improvement in heavily calloused skin has been demonstrated in as little as 3 weeks of once-daily use (manufacturer/retailer claim); no more precise onset timing for general use is published.
